Health Care/Hospital
CLASSYS Appoints Former Samsung Electronics Executive Vice President Jun-oh Yoon as CEO to Lead Its Next Stage of Global Growth
* Former Samsung Group and Samsung Electronics executive who led corporate growth strategy and major global M&A initiatives across the Corporate Strategy Office and DX Division * Brings extensive global leadership experience in business strategy, operations, and value creation across robotics...
2026-07-31 23:12
6544
Ridgetech, Inc. Reports Fiscal Year 2026 Financial Results
HANGZHOU, China, July 31, 2026 /PRNewswire/ -- Ridgetech, Inc. (Nasdaq: RDGT) ("Ridgetech" or the "Company"), a wholesale distributor of pharmaceutical and other healthcare products in China, today announced its financial results for the fiscal year ended March 31, 2026. Mr. Frank Zhao, Interim ...
2026-07-31 20:30
4484
Ractigen Therapeutics Announces U.S. FDA IND Clearance for First-in-Class saRNA Candidate RAG-1C to Treat Proliferative Vitreoretinopathy
* RAG-1C achieves dual IND clearances from both U.S. FDA and China CDE, paving the way for global clinical development of the world's first saRNA therapy for ocular diseases * RAG-1C utilizes Ractigen's clinically validated LiCO™ platform to target p21 gene activation for long-lasting anti-fi...
2026-07-31 19:00
2963
IMPACT Therapeutics Signs Exclusive License Agreement with Pharmanovia for Senaparib in Europe, Middle East and North Africa, Australia and New Zealand
SHANGHAI, July 31, 2026 /PRNewswire/ -- IMPACT Therapeutics ("IMPACT") (07630.HK) is pleased to announce that it has entered into an exclusive partnership (the "Exclusive Partnership") with Pharmanovia, a global specialty pharmaceutical company which partners with innovative biotech and large pha...
2026-07-31 15:48
1105
CellOrigin Unveils Two Novel Solid-Tumor Cell Therapy Candidates at ASCO 2026, Partners with Walvax for In Vivo CAR Clinical Trial
HANGZHOU, China, July 31, 2026 /PRNewswire/ -- CellOrigin, a biotechnology company focused on next-generation in vivo and in vitro cell therapy technologies, has announced two major progresses in both research and strategic partnership. At the 2026 ASCO Annual Meeting, CellOrigin's scientific co...
2026-07-31 14:15
1124
Amorepacific Holdings Signs Strategic Investment Agreement with HIGHER Corporation on Beauty and Medical Aesthetics Collaboration
Partnership to explore solutions connecting Amorepacific's skin science with HIGHER Corporation's medical aesthetics expertise SEOUL, South Korea, July 31, 2026 /PRNewswire/ -- Amorepacific Holdings announced that it signed a strategic investment agreement with HIGHER Corporation, a medical aest...
2026-07-31 10:36
1415
Telix H1 2026 Results: Investor Webcast Notification
MELBOURNE, Australia and INDIANAPOLIS, July 31, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today advises that it will release its financial results for the half-year ended June 30, 2026 on Thursday August 20, 2026. An investor webcast and conference call ...
2026-07-31 06:41
1145
Kuching to Host Asia's Leading Diabetes Experts at "Diabetes Asia 2026" Conference (DAC 2026)
KUCHING, Malaysia, July 30, 2026 /PRNewswire/ -- As diabetes continues to place an increasing burden on Malaysia's healthcare system — affecting an estimated 4.75 million Malaysian adults - Kuching will become the regional meeting point for leading diabetes experts this October as it hosts the "D...
2026-07-30 22:15
1660
AiRISTA Receives Frost & Sullivan's 2026 North American Competitive Strategy Leadership Recognition for Healthcare Real-Time Location Solutions
The company's interoperable RTLS platform, customer-centric strategy, and
continuous innovation are transforming healthcare asset management and
operational efficiency.
SAN ANTONIO, July 30, 2026 /PRNewswire/ -- Frost & Sullivan
2026-07-30 22:00
1221
HKEY-AI2Vivo™ 1.0: HKeyBio Accelerates In Vivo Translation for AI-Designed Candidates
HKEY-AI2Vivo™ 1.0 supports the move from computational hypotheses to in vivo translational evidence in autoimmune and allergy research BOSTON and SUZHOU, China, July 30, 2026 /PRNewswire/ -- HKeyBio has establishedHKEY-AI2Vivo™ 1.0, its AI Candidate In Vivo Validation Acceleration Program. The p...
2026-07-30 21:06
1028
Insilico Medicine Launches the Industry's First Drug Discovery and Development (DDD) Benchmark as a Service, to Evaluate Frontier AI and Foundation Models on Real-World Science
Leveraging 30+ validated PCC programs and over 12 years of model development experience to create a large-scale real-world "blind test" for frontier AI and foundation models, with a transparent public leaderboard. CAMBRIDGE, Mass., July 30, 2026 /PRNewswire/ -- As general-purpose and domain-spec...
2026-07-30 21:00
1225
NIPRO CORPORATION Receives FDA 510(k) Clearance for ELISIO™-HX, Introducing HDs to the United States
New medium-cutoff Dialyzer with a Super High-flux membrane brings NIPRO's approach to expanded hemodialysis to United States healthcare providers. OSAKA, Japan, July 30, 2026 /PRNewswire/ -- NIPRO CORPORATION has been granted 510(k) clearance for the ELISIO-HX dialyzer by the United States Food ...
2026-07-30 20:10
980
Continuity Biosciences Appoints Vicky Papoutsis to Board of Directors
Business development and corporate strategy executive joins Board as Company advances its clinical programs and partnering activity BRADENTON, Fla., July 30, 2026 /PRNewswire/ -- Continuity Biosciences today announced the appointment of Vicky Papoutsis to its Board of Directors. Vicky brings mor...
2026-07-30 20:00
733
Ping An Group Upgrades Longevity Management Service System, Unveils 11 Health Longevity Centers Nationwide
SHANGHAI, July 30, 2026 /PRNewswire/ -- Ping An Insurance (Group) Company of China, Ltd. ("Ping An Group") held a service upgrade press conference yesterday themed "Professionalism Safeguards a Century of Wellbeing", officially upgrading its "Ping An Health Longevity Management Service System". ...
2026-07-30 18:19
953
NMPA Accepts New Indication Application for Sacituzumab Tirumotecan (sac-TMT) as First-Line Treatment for Advanced TNBC
CHENGDU, China, July 30, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that a new indication application of its trophoblast cell-surface antigen 2 (TROP2)-directed antibody drug conjugate (ADC) sacituzumab tirumotecan...
2026-07-30 17:19
1003
As the Silver Economy Embraces AI: China's Elderly Care Innovation Competition Reveals Three Trends
SHANGHAI, July 30, 2026 /PRNewswire/ -- In Shanghai, China's city with the deepest aging population, a national competition focused on silver economy innovation has just concluded. The AID Silver Economy Creativity, Innovation and Entrepreneurship Competition, held by Shanghai Aging Industry Deve...
2026-07-30 16:46
1156
AIA Singapore expands cross-border medical access and digitalised care for more than 1 million employees
With over one-third (34%) of Singapore residents concerned over the affordability of healthcare services[1] and medical inflation projected to reach a record-high of 16.9%[2], AIA Singapore aims to bridge these cost and accessibility gaps with its upcoming corporate policy enhancements – all at ...
2026-07-30 11:00
3195
Propel Health Australia Highlights Emerging Research into Fulvic Acid and Microplastics
BRISBANE, Australia, July 30, 2026 /PRNewswire/ -- Propel Health is
highlighting new laboratory research published in Science of the Total
Environment showing that fulvic acid can interact directly with microplastic
particles under controlled conditions.
2026-07-30 08:01
961
Piramal Pharma Limited Announces Results for Q1 FY27
MUMBAI, India, July 29, 2026 /PRNewswire/ -- Piramal Pharma Limited (NSE: PPLPHARMA) (BSE: 543635), a leading global pharmaceutical, health and wellness company, today announced its standalone and consolidated results for the First Quarter (Q1) ended 30th June 2026. Consolidated Financial Hig...
2026-07-30 03:38
1410
Ractigen Therapeutics Closes Over $31 Million Financing to Advance Clinical-Stage saRNA Pipeline and Proprietary Extrahepatic Delivery Platforms
Funding led by Guozhong Capital will accelerate Phase 2 development for saRNA candidate RAG-01 and CNS asset RAG-17, advance systemic saRNA program RAG-18 toward IND, and expand extrahepatic RNA delivery technologies. NANTONG, China, July 29, 2026 /PRNewswire/ -- Ractigen Therapeutics, a clinica...
2026-07-29 21:57
1495
Week's Top Stories
Most Reposted
Franchising & Licensing Asia 2026 Opens New Chapter Under MP, Strengthening Singapore's Position as Asia's Franchise and Licensing Hub
[Picked up by 309 media titles]
2026-07-30 10:45
J.P. Morgan Private Bank Earns Record 10 Accolades at The Asset Triple A Private Capital Awards 2026
[Picked up by 294 media titles]
2026-07-30 15:00KC Global Media announces new travel series "AXN Ultimate Challenge: Sarawak"
[Picked up by 292 media titles]
2026-07-30 09:12
Articura Launches a New Chapter for Sovereign Healthcare AI in Indonesia
[Picked up by 291 media titles]
2026-07-27 19:02
ADA acquires Algonomy, strengthening its intelligent growth platform for a fully agentic experience
[Picked up by 290 media titles]
2026-07-30 15:30
Most Read
Franchising & Licensing Asia 2026 Opens New Chapter Under MP, Strengthening Singapore's Position as Asia's Franchise and Licensing Hub
2026-07-30 10:45
8388
Association of Trade and Commerce Reinforces Commitment to Supporting Singapore Enterprises Through Global Growth at The Entrepreneur Singapore 2026
2026-07-31 21:45
7514
Articura Launches a New Chapter for Sovereign Healthcare AI in Indonesia
2026-07-27 19:02
7309
KC Global Media announces new travel series "AXN Ultimate Challenge: Sarawak"
2026-07-30 09:12
7184